Danaher Corp (DHR) reported its first-quarter results. However, management expects steady growth in sales of solutions not covered by the COVID-19 pandemic in the coming quarters. As a result, Danaher improves its numbers for the current year.
Although the DHR stock’s main products during the COVID-19 public health crisis were coronavirus tests, as well as comprehensive equipment and solutions for vaccine and treatment developers, sales continued to grow despite the outbreak. This means an increase in the demand for goods that do not relate to the treatment of COVID-19 and its prevention, but an increase in the demand for solutions related to COVID-19 as well.
Revenue for Danaher Corp (DHR) biopharmaceutical segment increased 40% in the first quarter over the previous year. In the meantime, its management points out that its biopharmaceutical activities are growing like crazy not only due to COVID. Revenues are expected to reach $2 billion in the life sciences segment in 2021. Additionally, the DHR stock increased the forecast for a sold test from 36 million units to 45 million units.
Danaher is also likely to grow if children are immunized against COVID-19 or if they require a third dose of revaccination. Furthermore, the amount of research that appears to have been developed on vaccines could pave the way for the development of new vaccines and the COVID-19 virus may become endemic. Sales other than COVID-19 are projected to grow by more than 10% in 2021 for Danaher. Danaher’s income is less dependent on the pandemic thanks to different in-demand solutions available in different areas.
Danaher Corp (DHR) has demonstrated a variety of moving trends over the last few years. DHR Stocks gained 1.45% over the last week and 15.06% over the last month. Shares of this company rose by 12.25% during the last quarter. During the last six months, the stock has gained 7.01%, with a full-year gain of 55.53%. On a year-to-date (YTD) basis, the stock has seen a positive price performance of 15.50%.